Bladder cancer

First-line therapy of synchronous and metachronous metastatic UCa

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue

Educational Objective: Recognise which factors impact the choice of first-line therapy for synchronous or metachronous metastatic urothelial carcinoma (UCa), e.g. cisplatin eligibility, previous systemic therapy in the M0 setting, ECOG PS, PD-L1 status and FGFR2/3 alterations.
Specialty: Medical oncology, urology, clinical oncology, (radiation oncology)
Target Audience: CME (intermediate-advanced), Residents (senior)
Latest update: May 2024
Background:

Regulatory approval status of drugs limited to the metastatic UCa setting (status 31 May 2023)

ChT: chemotherapy; CPS: combined positive score; pts: patients